Mycoplasma pneumoniae carriage evades induction of protective mucosal antibodies

Ruben Cornelis Anthonie de Groot [1], Silvia Cristina Estevão [1], Patrick Michael Meyer Sauteur [2], Aditya Perkasa [1], Theo Hoogenboezem [3], Emiel Benny Margriet Spuesens [1], Lilly Maria Verhagen [4], Anna Maria Christiane van Rossum [5] and Wendy Wilhelmina Josephina Unger [1]

[1]Dept of Pediatrics, Laboratory of Pediatrics, Erasmus MC University Medical Centre Rotterdam – Sophia Children's Hospital, Rotterdam, The Netherlands. [2]Division of Infectious Diseases and Hospital Epidemiology, University Children's Hospital Zurich, Zurich, Switzerland. [3]Dept of Pediatrics, Van Weel Bethesda Hospital, Dirksland, The Netherlands. [4]Dept of Pediatrics, Immunology and Infectious Diseases, Wilhelmina Children's Hospital, University Medical Centre Utrecht, Utrecht, The Netherlands. [5]Dept of Pediatrics, Division of Paediatric Infectious Diseases and Immunology, Erasmus MC University Medical Centre Rotterdam – Sophia Children's Hospital, Rotterdam, The Netherlands.

Corresponding author: Wendy W.J. Unger (w.unger@erasmusmc.nl)

Shareable abstract (@ERSpublications)
Antibodies against *M. pneumoniae*, the most common bacterial cause of pneumonia in children, are able to prevent adhesion of *M. pneumoniae* to epithelial cells, but are only induced during infection and not during asymptomatic carriage https://bit.ly/3CNdAhM

Cite this article as: de Groot RCA, Estevão SC, Meyer Sauteur PM, *et al*. *Mycoplasma pneumoniae* carriage evades induction of protective mucosal antibodies. *Eur Respir J* 2022; 59: 2100129 [DOI: 10.1183/13993003.00129-2021].

Copyright ©The authors 2022.

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org

Received: 14 Jan 2021
Accepted: 5 Aug 2021

Abstract

Background *Mycoplasma pneumoniae* is the most common bacterial cause of pneumonia in children hospitalised for community-acquired pneumonia (CAP). Prevention of infection by vaccines may be an important strategy in the presence of emerging macrolide-resistant *M. pneumoniae*. However, knowledge of immune responses to *M. pneumoniae* is limited, complicating vaccine design.

Methods We studied the antibody response during *M. pneumoniae* respiratory tract infection and asymptomatic carriage in two different cohorts.

Results In a nested case–control study (n=80) of *M. pneumoniae* carriers and matched controls we observed that carriage by *M. pneumoniae* does not lead to a rise in either mucosal or systemic *M. pneumoniae*-specific antibodies, even after months of persistent carriage. We replicated this finding in a second cohort (n=69) and also found that during *M. pneumoniae* CAP, mucosal levels of *M. pneumoniae*-specific IgA and IgG did increase significantly. *In vitro* adhesion assays revealed that high levels of *M. pneumoniae*-specific antibodies in nasal secretions of paediatric patients prevented the adhesion of *M. pneumoniae* to respiratory epithelial cells.

Conclusions Our study demonstrates that *M. pneumoniae*-specific mucosal antibodies protect against bacterial adhesion to respiratory epithelial cells, and are induced only during *M. pneumoniae* infection and not during asymptomatic carriage. This is strikingly different from carriage with bacteria such as *Streptococcus pneumoniae* where mucosal antibodies are induced by bacterial carriage.

Introduction

Upper respiratory tract carriage is essential for the life cycle of many bacterial respiratory pathogens, such as *Streptococcus pneumoniae*, *Staphylococcus aureus* and *Mycoplasma pneumoniae*. *M. pneumoniae* highly depends on the host for essential nutrients, such as amino acids, cholesterol and folic acid, since it has limited metabolic capacity because of its small genome [1]. *M. pneumoniae* therefore strongly adheres to upper respiratory tract epithelial cells using a specialised multiprotein adhesion complex consisting of adhesins such as P1 [2]. *M. pneumoniae* carriage can last for several months and is in itself asymptomatic [3–5]. However, *M. pneumoniae* carriage can lead to disease since carriage can precede infection of the host, resulting in symptomatic respiratory infection by *M. pneumoniae*. Furthermore, *M. pneumoniae* carriage also forms a reservoir for horizontal transmission to other hosts that are in close contact.



Horizontal transmission often occurs within families, children in long-term care facilities and among military recruits [6–11].

Pneumonia is a major cause of morbidity and mortality among children worldwide, and *M. pneumoniae* is the most common cause of bacterial pneumonia in children [12–14]. Although *M. pneumoniae* generally causes moderately severe cases of pneumonia, *M. pneumoniae* can lead to severe pneumonia and can be accompanied by severe extrapulmonary manifestations [15]. Treatment of *M. pneumoniae* pneumonia can be challenging in countries with a high prevalence of macrolide-resistant *M. pneumoniae*, since other classes of antibiotics that target cell wall synthesis are not effective as mycoplasmas lack a cell wall. Furthermore, quinolones and tetracyclines, which like macrolides work on other bacterial targets, are not routinely recommended in children because of concerns about toxicity [16]. A *M. pneumoniae* vaccine is currently unavailable, but could potentially prevent morbidity and hospitalisation in children, especially where the incidence of (macrolide-resistant) *M. pneumoniae* is high, *e.g.* in East Asia [14, 17]. The development of such a vaccine is hampered by a lack of knowledge of mucosal immunity to *M. pneumoniae* carriage, since carriage is essential for subsequent infection and horizontal transmission.

The asymptomatic presence of a potential pathogen in the upper respiratory tract can be divided into two distinct phases: 1) acquisition of carriage is the introduction of a microorganism in a host and 2) carriage is the persistent presence of a microorganism that has been successfully introduced in the upper respiratory tract. However, data on what immune responses are required to clear *M. pneumoniae* from the nasal mucosa during each phase are limited. In contrast, this has been well described for *S. pneumoniae*: *S. pneumoniae*-specific antibodies have been shown to be important to prevent acquisition of *S. pneumoniae* carriage, whereas T-helper type 17-mediated recruitment of phagocytes is known to be important for clearance of persistent *S. pneumoniae* carriage [18–21]. Studies in patients with invasive *M. pneumoniae* infections and murine carriage studies suggest there could be a role for *M. pneumoniae*-specific antibodies in *M. pneumoniae* carriage [22–25].

In the present study we therefore determined the presence and the function of *M. pneumoniae*-specific antibodies in the upper respiratory tract of children. We hypothesised that mucosal antibodies are induced during upper respiratory tract carriage of *M. pneumoniae* in children and that these antibodies can interfere with *M. pneumoniae*'s most important virulence factor: attachment to the respiratory epithelium.

Methods

Cohort 1: M. pneumoniae *carriage in asymptomatic children*

We performed a nested case–control study within a previously published cohort of asymptomatic children (n=405) who underwent elective surgery [3]. We considered 50% higher levels of mucosal *M. pneumoniae*-specific IgA in *M. pneumoniae* carriers compared with noncarrier controls to be a biologically relevant difference. Based on a sample size calculation with α set at 5%, desired power at 90% and expected loss of samples due to insufficient quantity or quality of available nasal lavage samples of 10%, we selected 40 *M. pneumoniae* carriers and 40 noncarrier controls. Cases of *M. pneumoniae* carriage were defined as those children without current or recent symptoms of respiratory tract disease who had a *M. pneumoniae* quantitative PCR (qPCR)-positive upper respiratory tract sample, *i.e.* pharyngeal swab and/or nasal lavage sample. All cases, *i.e. M. pneumoniae* carriers, were matched 1:1 based on age (<1 year age difference) and on date of inclusion to account for seasonality (<60 days apart) to noncarrier controls, defined as children without respiratory symptoms who were *M. pneumoniae* qPCR-negative. Upper respiratory tract samples were taken at inclusion and monthly follow-up samples were available for a subset of patients. Upper respiratory tract samples were analysed for the presence of *M. pneumoniae*-specific and total IgA, IgM and IgG antibody levels.

Cohort 2: M. pneumoniae *carriage and respiratory tract infection*

We analysed all available pharyngeal swab samples available from a prospective observational longitudinal cohort study [26] that included asymptomatic *M. pneumoniae* carriers, noncarrier controls, and children with *M. pneumoniae* community-acquired pneumonia (CAP) and non-*M. pneumoniae* CAP. CAP was defined as a clinical diagnosis with fever >38.5°C and tachypnoea according to British Thoracic Society guidelines, and children aged 3–18 years were included [26]. *M. pneumoniae* CAP patients were positive for pharyngeal swab *M. pneumoniae* qPCR and *M. pneumoniae*-specific antibody-secreting cells (ASCs) in peripheral blood, whereas non-*M. pneumoniae* CAP patients were negative for both. Pharyngeal swab samples were taken at inclusion, visit 2 (2 weeks to 2 months post-onset of symptoms) and visit 3 (2–6 months post-onset of symptoms). Samples were measured for *M. pneumoniae*-specific and total mucosal and systemic antibody levels.

Detection and function of nasal lavage M. pneumoniae*-specific and total immunoglobulin*

Levels of total and *M. pneumoniae*-specific IgA, IgM and IgG were measured using an in-house ELISA assay (supplementary material). Serum samples were considered seropositive for *M. pneumoniae* when measured specific antibody levels exceeded that of a reference control of pooled sera of patients without *M. pneumoniae* infection (Virion\Serion, Wurzburg, Germany). To assess a potential inhibitory effect of nasal lavage antibodies on *M. pneumoniae* epithelial adhesion, A549 respiratory epithelial cells were incubated with diluted nasal lavage samples and subsequently 10^9 CFU per well of *M. pneumoniae* strain M129 were added. After 4 h incubation, unbound bacteria were washed off and adhering bacteria counted on PPLO (pleuropneumonia-like organism) agar plates (supplementary material).

Statistical analysis

Prism version 5 (GraphPad, San Diego, CA, USA), G*Power version 3.1.9.7 (Universität Düsseldorf, Düsseldorf, Germany) and IBM SPSS Statistics version 25 (IBM, Armonk, NY, USA) were used for statistical analysis. The t-test and Mann–Whitney U-test were used to compare groups. Pearson's correlation coefficient and Spearman's rank correlation coefficient were used for statistical significance testing and quantifying the magnitude of correlations. The paired t-test and McNemar's test were used to compare multiple samples from the same patient and to compare matched patients. Tests are two-sided unless otherwise reported and α was set at 0.05.

Results

Asymptomatic carriage with M. pneumoniae *does not increase mucosal* M. pneumoniae*-specific antibody levels*

To study the role of *M. pneumoniae*-specific antibodies in the upper respiratory tract we first investigated if mucosal *M. pneumoniae*-specific antibodies are induced in asymptomatic children during *M. pneumoniae* carriage. We therefore performed a nested case–control study within cohort 1 and compared *M. pneumoniae* carriers with noncarrier controls (table 1). Assessment of *M. pneumoniae*-specific IgA in nasal lavage revealed that *M. pneumoniae*-specific IgA levels were not significantly different between *M. pneumoniae* carriers and noncarrier controls (p=0.230) (figure 1a). Similar observations were made for *M. pneumoniae*-specific IgG (p=0.351) and IgM (p=0.385) (figure 1b and c). Importantly, nasal lavage *M. pneumoniae*-specific IgM levels were below the detection limit in 45.6% (n=36/79) of study subjects. Since *M. pneumoniae* carriers could have acquired *M. pneumoniae* too recently to have developed a mucosal antibody response [18, 27], we analysed monthly follow-up nasal lavage samples of *M. pneumoniae* carriers. No increase in levels of *M. pneumoniae*-specific IgA or IgG in nasal lavage was detected over the course of 2 months (figure 1d and e). Furthermore, mean levels of total IgA, IgG and IgM in nasal lavage were not different between *M. pneumoniae* carriers and noncarrier controls (supplementary figure S1). On average, nasal lavage levels of total IgA were >70 times higher than total IgG levels, which in turn were 10-fold higher than total IgM levels (supplementary figure S1). In addition to mucosal antibody levels we also evaluated the presence of systemic *M. pneumoniae*-specific antibody levels in response to *M. pneumoniae* carriage, since systemic antibody responses to respiratory tract carriage have been shown for *S. pneumoniae* and *S. aureus* [18, 28]. Again, no significant difference in the prevalence of serum *M. pneumoniae*-specific IgM (19% *versus* 11%), serum *M. pneumoniae*-specific IgA (0% *versus* 2.8%) or serum *M. pneumoniae*-specific IgG (25% *versus*

TABLE 1 *Mycoplasma pneumoniae* carriers and age- and season-matched noncarrier controls from cohort 1

	Noncarrier controls (n=40)	*M. pneumoniae* carriers (n=40)	p-value
Sex			
Male	25	25	NS[#]
Female	15	15	
Mean (range) age, years	4.54 (0.4–16.0)	4.57 (0.4–16.8)	NS[¶]
Year			
2009	11	11	NS
2010	16	16	
2011	13	13	
Positive *M. pneumoniae*-specific IgM in serum, % (95% CI) (n/N)	11 (3–22) (4/36)	19 (6–34) (6/32)	NS[#]
Positive *M. pneumoniae*-specific IgA in serum, % (95% CI) (n/N)	2.8 (0–8) (1/36)	0 (0–0) (0/32)	NS[#]
Positive *M. pneumoniae*-specific IgG in serum, % (95% CI) (n/N)	17 (6–31) (6/36)	25 (12–42) (8/32)	NS[#]
Median (IQR) URT *M. pneumoniae* load, copy number·mL^{-1}	0 (0–0)	2653 (424–23 075)	<0.001[+]

Data are presented as n, unless otherwise stated. IQR: interquartile range; URT: upper respiratory tract. #: related samples McNemar test; ¶: paired t-test; +: related samples Wilcoxon signed-rank test. NS: nonsignificant.



FIGURE 1 *Mycoplasma pneumoniae* upper respiratory tract colonisation does not induce a mucosal *M. pneumoniae*-specific antibody response. a–c) Cohort 1 nasal lavage samples of age- and season-matched *M. pneumoniae* carriers (n=39/40) and healthy controls (n=40/40) were analysed by ELISA for levels of *M. pneumoniae*-specific a) IgA, b) IgG and c) IgM. d, e) *M. pneumoniae*-specific d) IgA and e) IgG levels in nasal lavage of *M. pneumoniae* carriers (n=10) over the course of 2 months. Lines and error bars represent geometric means with 95% confidence interval. NS: nonsignificant (paired t-test).

17%) (table 1) was detected between *M. pneumoniae* carriers and noncarrier controls at inclusion. Since our findings on *M. pneumoniae* are in contrast to data on *S. pneumoniae*, which does induce mucosal antibody production during carriage [18], we measured *M. pneumoniae*-specific immunoglobulins in nasal lavage of asymptomatic children from an independent cohort (cohort 2) [3, 26]. Within this second cohort we again compared *M. pneumoniae* carriers and noncarrier controls (n=29). Similar to our observations in cohort 1, both *M. pneumoniae*-specific IgA (supplementary figure S2a) and *M. pneumoniae*-specific IgG (supplementary figure S2b) in nasal lavage were not significantly different between *M. pneumoniae* carriers and noncarrier controls.

Taken together, our data show that asymptomatic carriage of *M. pneumoniae* in the upper respiratory tract does not induce a mucosal or a systemic antibody response.

Mucosal specific antibody levels increase upon symptomatic M. pneumoniae *infection*

Next we assessed if during lower respiratory tract infection *M. pneumoniae* does induce the production of *M. pneumoniae*-specific antibodies in the upper respiratory tract, as this has been shown in experimental *M. pneumoniae* infection [25]. Thus, we examined nasal lavage samples from cohort 2, where *M. pneumoniae* CAP patients were distinguished from non-*M. pneumoniae* CAP patients by the presence

TABLE 2 Cohort 2 (non-)*Mycoplasma pneumoniae* community-acquired pneumonia (CAP) patients

	Non-*M. pneumoniae* CAP controls[#] (n=22)	*M. pneumoniae* CAP[#] (n=18)	p-value
Sex			
Male	13	11	NS[¶]
Female	9	7	
Mean (95% CI) age, years	6.61 (5.4–8.0)	8.89 (7.9–9.6)	0.033[+]
Year			
2016	20	15	NS[¶]
2017	2	3	
Median (IQR) URT *M. pneumoniae* load, copy number·mL^{-1}	0 (0–0)	16 799 (2215–82 852)	0.001[§]
Median (range) *M. pneumoniae*-specific IgM ASCs, spots per 10^{6} PBMCs		185 (47–775)	

Data are presented as n, unless otherwise stated. IQR: interquartile range; URT: upper respiratory tract; ASC: antibody-secreting cell; PBMC: peripheral blood mononuclear cell. [#]: *M. pneumoniae* CAP is defined as *M. pneumoniae* quantitative PCR (qPCR)-positive on URT sample and *M. pneumoniae*-specific IgM ASC-positive in peripheral blood, whereas non-*M. pneumoniae* CAP patients were both *M. pneumoniae* qPCR- and ASC-negative; [¶]: Chi-squared test; [+]: t-test with Welch's correction; [§]: independent samples Mann–Whitney U-test. NS: nonsignificant.

of *M. pneumoniae*-specific ASCs in peripheral blood (table 2) [26]. We compared *M. pneumoniae*-specific IgA and IgG in nasal lavage samples taken >10 days after the first clinical symptoms with antibody levels in nasal lavage samples from the same patients taken early during the infection (⩽10 days post-onset of symptoms). We observed that *M. pneumoniae* CAP patients developed mucosal *M. pneumoniae*-specific antibodies 10 days after onset of symptoms, consistent with the kinetics of antibody responses to other pathogens [29]. A significant increase in levels of both *M. pneumoniae*-specific IgA (geometric mean 3.66 *versus* 32.8 AU·mL^{-1}; p=0.033) as well as *M. pneumoniae*-specific IgG (geometric mean 2.35 *versus* 26.6 AU·mL^{-1}; p=0.038) was measured (figure 2a and b). Mucosal antibody levels remained elevated in follow-up samples taken at 1–2 months post-onset of symptoms. To confirm that these responses were specific to *M. pneumoniae* infection we assessed mucosal specific antibody levels of non-*M. pneumoniae* CAP patients. We found that both *M. pneumoniae*-specific IgA and IgG were significantly higher in nasal lavage of *M. pneumoniae* CAP patients (n=15) compared with non-*M. pneumoniae* CAP (n=18) (figure 2a and b). We made similar observations for systemic antibody responses, *i.e. M. pneumoniae*-specific IgA and IgG in serum (data not shown).

Mucosal M. pneumoniae*-specific antibodies correlate with* M. pneumoniae *load in the upper respiratory tract of children with* M. pneumoniae *CAP*

Although levels of mucosal *M. pneumoniae*-specific IgA were elevated in *M. pneumoniae* CAP patients following infection (>10 days post-onset of symptoms), there was considerable variation in specific IgA levels between patients. We hypothesised that the height of the antibody response would be determined by the level of immune stimulation, which in turn would depend on the bacterial load. Indeed, *M. pneumoniae*-specific IgA levels in nasal lavage positively correlated (Spearman's ρ=0.589, 95% CI 0.133–0.850; p=0.021) with bacterial load in the upper respiratory tract as determined by *M. pneumoniae* copy numbers (figure 2c). We observed that the IgG response followed a similar pattern as there was a strong correlation between mucosal *M. pneumoniae*-specific IgA and *M. pneumoniae*-specific IgG in *M. pneumoniae*-infected patients (Pearson's r=0.879, 95% CI 0.756–0.946; p<0.001) (supplementary figure S2c).

In summary, in contrast to *M. pneumoniae* carriage, symptomatic lower respiratory tract infection by *M. pneumoniae* clearly induced the production of mucosal *M. pneumoniae*-specific IgA and IgG, levels of which showed a moderately strong correlation with *M. pneumoniae* load in the upper respiratory tract.

Mucosal M. pneumoniae*-specific antibodies are directed against components of the* M. pneumoniae *attachment organelle*

We then assessed against which *M. pneumoniae* epitopes the mucosal antibody response could be directed, since this information would be essential for the design of a *M. pneumoniae* vaccine. We hypothesised that the antibody response would for a substantial part be directed to *M. pneumoniae*'s attachment organelle and therefore focused on immunodominant *M. pneumoniae* proteins that are known to be involved in bacterial adhesion to the respiratory epithelium, *i.e.* P1, P30 and P116 [30, 31]. When comparing



FIGURE 2 *Mycoplasma pneumoniae* infection induces an increase in mucosal *M. pneumoniae*-specific antibody levels. a, b) Cohort 2 nasal lavage samples of *M. pneumoniae* community-acquired pneumonia (CAP) (n=9–15/18) and non-*M. pneumoniae* CAP patients (n=14–18/22) were analysed by ELISA for levels of *M. pneumoniae*-specific a) IgA and b) IgG. Lines and error bars represent geometric means with 95% CI. c) Genomic copy numbers of *M. pneumoniae* in the upper respiratory tract as determined by PCR in relation to upper respiratory tract levels of *M. pneumoniae*-specific IgA in *M. pneumoniae* CAP patients at >10 days post-onset of symptoms (n=15/18). *: p<0.05; ***: p<0.001; NS: nonsignificant (paired t-test for ⩽10 *versus* >10 days and unpaired t-test for other comparisons).

M. pneumoniae CAP patient nasal lavage samples taken early *versus* those that were collected later during infection, we found that mucosal antibodies against P1, P30 as well as P116 were being induced in the upper respiratory tract during *M. pneumoniae* infection (tables 3 and 4). Antibody responses against these adhesins were absent in non-*M. pneumoniae* CAP patients, indicating that these antibodies were specific to infection with *M. pneumoniae* (supplementary table S2). IgA and IgG specific to the adhesion proteins were also present in *M. pneumoniae* carriers and noncarriers, albeit at lower levels than in *M. pneumoniae* CAP patients (supplementary table S2).

Mucosal M. pneumoniae-*specific antibodies prevent* M. pneumoniae *adhesion to respiratory epithelial cells*

The finding that mucosal specific IgA and IgG antibodies were not elevated in *M. pneumoniae* carriers raised the question if these antibodies have any protective role [32], especially since we found that mucosal antibodies are directed against *M. pneumoniae* proteins P1, P30 and P116, which are involved in

TABLE 3 Nasal lavage specific IgA antibody levels induced against *Mycoplasma pneumoniae* protein fragments P1, P30 and P116 in individual *M. pneumoniae* community-acquired pneumonia patients at both early (⩽10 days post-onset of symptoms) and later (>10 days post-onset of symptoms) time-points

IgA	Patient 1		Patient 2		Patient 3		Patient 4		Patient 5	
	⩽10 days	>10 days	⩽10 days	>10 days	⩽10 days	>10 days	⩽10 days	>10 days	⩽10 days	>10 days
$P1_{1287–1518}$	–	+++	–	+	++	+	–	+	–	++
$P1_{694–787}$	–	+++	–	–	++	–	–	–	–	+
$P30_{17–71}$	–	–	–	–	++	–	–	–	–	–
$P30_{98–274}$	+	++	+	+	+++	+	+	+	+	+
P116	+	+	–	+	+++	+	–	+	–	+

–: below detection limit; +: 1–1.5× detection limit; ++: 1.5–2× detection limit; +++: >2× detection limit.

attachment to epithelium. We thus assessed the ability of *M. pneumoniae*-specific antibodies from nasal lavage of children to prevent adhesion of *M. pneumoniae* to respiratory epithelium in an *in vitro* adhesion assay. We found that nasal lavage containing low levels of *M. pneumoniae*-specific IgA and IgG did not block the adhesion of *M. pneumoniae* to A549 cells, whereas nasal lavage containing high levels did prevent *M. pneumoniae* adhesion (figure 3a and b). This interference with bacterial adhesion was more strongly associated with *M. pneumoniae*-specific IgA levels (Spearman's $\rho=-0.544$, 95% CI −0.806–−0.197; p=0.001) than with *M. pneumoniae*-specific IgG levels (Spearman's $\rho=-0.358$, 95% CI −0.690–0.050; p=0.041). Importantly, interference with bacterial adhesion was not correlated with levels of total IgA, total IgG or levels of total protein in nasal lavage (data not shown), which excluded that these factors confounded our observation that *M. pneumoniae*-specific antibodies prevented *M. pneumoniae* adhesion to respiratory epithelial cells.

Taken together, these results show that *M. pneumoniae*-specific antibodies present in the upper respiratory tract of children can prevent *M. pneumoniae* adhesion to respiratory epithelial cells.

Discussion

Our study provides novel insights into humoral immunity to *M. pneumoniae* carriage in children. These data are the basis for the design of a *M. pneumoniae* vaccine that interferes with carriage, and subsequently *M. pneumoniae* infection and transmission, ultimately lowering the burden of pneumonia on child health [33]. Furthermore, our study increases our understanding of the dynamics of upper respiratory carriage by respiratory pathogens by showing the differences in mucosal antibody response between *M. pneumoniae* and other pathogens such as *S. pneumoniae* and *S. aureus*.

Surprisingly, mean levels of mucosal and systemic *M. pneumoniae*-specific and total antibodies were not elevated in children carrying *M. pneumoniae* when compared with noncarrier controls, even after 2 months of persistent carriage, which should be sufficient for the induction of an antibody response. Several studies have shown that systemic *M. pneumoniae*-specific immunoglobulins can be detected in *M. pneumoniae* carriers and noncarrier controls, suggesting that these are the result of recent infection in those patients [3, 26]. The absence of an antibody response to *M. pneumoniae* carriage is in contrast to findings on *S. pneumoniae* and *S. aureus* carriage, where carriage with these pathogens has been shown to elevate

TABLE 4 Nasal lavage specific IgG antibody levels induced against *Mycoplasma pneumoniae* protein fragments P1, P30 and P116 in individual *M. pneumoniae* community-acquired pneumonia patients

IgG	Noncarriers					*M. pneumoniae* carriers				
	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6	Patient 7	Patient 8	Patient 9	Patient 10
$P1_{1287–1518}$	–	–	+	+	–	–	+	+	–	+
$P1_{694–787}$	–	–	–	++	++	–	–	–	–	+++
$P30_{17–71}$	–	–	++	+	+	–	–	–	–	+
$P30_{98–274}$	+	+	+++	++	+	+	+	–	+	++
P116	–	+	+++	+	++	–	+	+	–	+++

–: below detection limit; +: 1–1.5× detection limit; ++: 1.5–2× detection limit; +++: >2× detection limit.



FIGURE 3 *Mycoplasma pneumoniae*-specific antibodies in nasal secretions block the adhesion of *M. pneumoniae* to respiratory epithelial cells. Adhesion of *M. pneumoniae* to A549 cells *in vitro* when cultured in the presence or absence of *M. pneumoniae*-specific antibodies containing nasal lavage from both cohort 1 and 2 (n=33). Number of adhering bacteria (expressed as CFU) in relation to *M. pneumoniae*-specific a) IgA or b) IgG levels in nasal secretions.

specific, mucosal or systemic IgA and IgG [18, 28]. It seems unlikely that our results can be explained by an inability to mount a mature antibody response, since the majority of the children in our cohorts were aged >4 years old and none had underlying diseases. The absence of antibody induction in response to *M. pneumoniae* carriage is therefore probably related to bacteria-intrinsic factors and/or differences in bacterial behaviour compared with *S. pneumoniae* and *S. aureus*. Indeed, during carriage *M. pneumoniae* is thought to rest on the upper respiratory tract epithelium [25], whereas *S. pneumoniae* can cross the epithelium into the lamina propria even during carriage [34]. These so-called micro-invasions of *S. pneumoniae* and subsequent activation of the immune system could lead to induction of an antibody response during *S. pneumoniae* carriage. Another explanation for the absence of an antibody response to *M. pneumoniae* carriage could be that *M. pneumoniae* cell membranes contain less immunogenic lipoproteins or glycolipids compared with *S. pneumoniae* and *S. aureus*, resulting in less immune activation. Furthermore, *M. pneumoniae* could possibly even actively downregulate the host immune response.

We show that mucosal *M. pneumoniae*-specific antibodies are directed against key proteins of *M. pneumoniae*'s attachment organelle, *i.e.* P1, P30 and P116, which is in line with previous studies that associated the presence of antibodies in the upper respiratory tract with protection against *M. pneumoniae*. Furthermore, our *in vitro* data indicate that when present at high levels, *M. pneumoniae*-specific antibodies in nasal lavage of children inhibit *M. pneumoniae* adherence to respiratory epithelial cells. Sufficiently high antibody levels are likely to be present in the upper respiratory tract of children, since in our *in vitro* adhesion assay we used 10-fold diluted samples, which still efficiently blocked bacterial adhesion. In our adhesion assay we did not evaluate if specific antibodies could clear existing carriage of *M. pneumoniae*, since in our *in vitro* assay *M. pneumoniae*-specific antibodies were added before bacterial suspensions. However, in a murine model of *M. pneumoniae* post-infectious carriage, we previously observed that bacterial loads were higher in the upper respiratory tract of B-cell-deficient mice compared with wild-type mice, suggesting specific antibodies can clear existing carriage [25]. Interestingly, passive immunisation with serum from infected wild-type mice did not rescue clearance of *M. pneumoniae* from the upper respiratory tract in B-cell-deficient mice, indicating that mucosal instead of systemic antibodies are essential to clear *M. pneumoniae* carriage.

M. pneumoniae-specific mucosal IgA showed a stronger correlation with ability to block bacterial adhesion compared with *M. pneumoniae*-specific mucosal IgG. This does not preclude a role for IgG in blocking bacterial adhesion, but rather suggests that specific IgA is more important. Colinearity between *M. pneumoniae*-specific IgA and IgG levels prevented us from dissecting the relative importance of both isotypes. Importantly, *M. pneumoniae*-specific IgG could additionally contribute to immunity to *M. pneumoniae* carriage by activating complement and opsonising bacteria to enhance phagocytosis [35].

In our cohorts of *M. pneumoniae* carriers only one patient had strongly elevated *M. pneumoniae*-specific antibodies. Given that *M. pneumoniae* infection results in robust induction of mucosal antibodies that

remain in the upper respiratory tract for months, this observation suggests that primary *M. pneumoniae* carriage is much more prevalent than post-infectious carriage. Furthermore, our finding also suggests that immunity after *M. pneumoniae* infection might offer protection against post-infectious *M. pneumoniae* carriage. This is supported by a study in human volunteers where pre-existing levels of respiratory tract *M. pneumoniae*-specific IgA correlated with protection against experimental infection [32].

Our study has several strengths and limitations. An important strength of our study is that both cohorts of patients contain data for multiple time-points on *M. pneumoniae* carriers and *M. pneumoniae* CAP patients. Furthermore, both cohorts contain relevant matched control groups of noncarriers and non-*M. pneumoniae* CAP patients. A limitation is that due to the design of the study we were unable to evaluate if mucosal *M. pneumoniae*-specific antibodies are able to protect children against a subsequent episode of pneumonia.

In summary, in this study we show that only during symptomatic infection and not during asymptomatic carriage with *M. pneumoniae*, there is an induction of mucosal and systemic *M. pneumoniae*-specific antibodies. This is a striking disparity with immunity to other respiratory pathogens such as *S. pneumoniae* and *S. aureus*, suggesting that the immune response to microbial carriage in the respiratory tract differs between pathogens. Mucosal *M. pneumoniae*-specific antibodies effectively prevented adhesion to respiratory epithelial cells. Considering that *M. pneumoniae* largely depends on host nutrients, maintaining adherence to the upper respiratory tract epithelium by preventing mucosal antibody induction could be essential for *M. pneumoniae* survival and transmission to other hosts.

Acknowledgements: We would like to thank all patients and their caretakers for their participation in these studies.

Author contributions: R.C.A. de Groot, A.M.C. van Rossum and W.W.J. Unger conceived the project, interpreted data and drafted the manuscript. R.C.A. de Groot, S.C. Estevão, P.M. Meyer Sauteur, A. Perkasa and T. Hoogenboezem conducted and analysed experiments. P.M. Meyer Sauteur and E.B.M. Spuesens collected patient samples. P.M. Meyer Sauteur and L.M. Verhagen interpreted data. All authors critically reviewed the manuscript and made intellectual contributions to the study.

Conflict of interest: None declared.

Support statement: This study was supported by a grant from the Sophia Scientific Research Foundation (SSWO 2018-04/WO) and Stichting Coolsingel (503). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

References

1. Yus E, Maier T, Michalodimitrakis K, *et al.* Impact of genome reduction on bacterial metabolism and its regulation. *Science* 2009; 326: 1263–1268.
2. Waites KB, Xiao L, Liu Y, *et al. Mycoplasma pneumoniae* from the respiratory tract and beyond. *Clin Microbiol Rev* 2017; 30: 747–809.
3. Spuesens EB, Fraaij PL, Visser EG, *et al.* Carriage of *Mycoplasma pneumoniae* in the upper respiratory tract of symptomatic and asymptomatic children: an observational study. *PLoS Med* 2013; 10: e1001444.
4. Wood PR, Hill VL, Burks ML, *et al. Mycoplasma pneumoniae* in children with acute and refractory asthma. *Ann Allergy Asthma Immunol* 2013; 110: 328–334.
5. Meyer Sauteur PM, Truck J, van Rossum AMC, *et al.* Circulating antibody-secreting cell response during *Mycoplasma pneumoniae* childhood pneumonia. *J Infect Dis* 2020; 222: 136–147.
6. Kannan TR, Hardy RD, Coalson JJ, *et al.* Fatal outcomes in family transmission of *Mycoplasma pneumoniae*. *Clin Infect Dis* 2012; 54: 225–231.
7. Gdalevich M, Haas EJ, Dukhan L, *et al.* Control of a *Mycoplasma pneumoniae* outbreak in an institutional setting using azithromycin prophylaxis. *Front Public Health* 2017; 5: 366.
8. Cordero L, Cuadrado R, Hall CB, *et al.* Primary atypical pneumonia: an epidemic caused by *Mycoplasma pneumoniae*. *J Pediatr* 1967; 71: 1–12.
9. Biberfeld G, Sterner G. A study of *Mycoplasma pneumoniae* infections in families. *Scand J Infect Dis* 1969; 1: 39–46.
10. Chanock RM, Fox HH, James WD, *et al.* Epidemiology of *M. pneumoniae* infection in military recruits. *Ann NY Acad Sci* 1967; 143: 484–496.
11. Meyer Sauteur PM, Krautter S, Ambroggio L, *et al.* Improved diagnostics help to identify clinical features and biomarkers that predict *Mycoplasma pneumoniae* community-acquired pneumonia in children. *Clin Infect Dis* 2019; 71: 1645–1654.

12 World Health Organization. Pneumonia fact sheet. 2016. www.who.int/news-room/fact-sheets/detail/pneumonia Date last accessed: 16 April 2018.

13 Jain S, Williams DJ, Arnold SR, *et al.* Community-acquired pneumonia requiring hospitalisation among U.S. children. *N Engl J Med* 2015; 372: 835–845.

14 Benet T, Sanchez Picot V, Messaoudi M, *et al.* Microorganisms associated with pneumonia in children <5 years of age in developing and emerging countries: the GABRIEL pneumonia multicenter, prospective, case-control study. *Clin Infect Dis* 2017; 65: 604–612.

15 de Groot RCA, Meyer Sauteur PM, Unger WWJ, *et al.* Things that could be *Mycoplasma pneumoniae*. *J Infect* 2017; 74: Suppl. 1, S95–S100.

16 Lin K, Zahlanie Y, Ortwine JK, *et al.* Decreased outpatient fluoroquinolone prescribing using a multimodal antimicrobial stewardship initiative. *Open Forum Infect Dis* 2020; 7: ofaa182.

17 Meyer Sauteur PM, Unger WW, Nadal D, *et al.* Infection with and carriage of *Mycoplasma pneumoniae* in children. *Front Microbiol* 2016; 7: 329.

18 Ferreira DM, Neill DR, Bangert M, *et al.* Controlled human infection and rechallenge with *Streptococcus pneumoniae* reveals the protective efficacy of carriage in healthy adults. *Am J Respir Crit Care Med* 2013; 187: 855–864.

19 Zhang Z, Clarke TB, Weiser JN. Cellular effectors mediating Th17-dependent clearance of pneumococcal colonisation in mice. *J Clin Invest* 2009; 119: 1899–1909.

20 Mitsi E, Roche AM, Reine J, *et al.* Agglutination by anti-capsular polysaccharide antibody is associated with protection against experimental human pneumococcal carriage. *Mucosal Immunol* 2017; 10: 385–394.

21 Wang Y, Jiang B, Guo Y, *et al.* Cross-protective mucosal immunity mediated by memory Th17 cells against *Streptococcus pneumoniae* lung infection. *Mucosal Immunol* 2017; 10: 250–259.

22 Taylor-Robinson D, Gumpel JM, Hill A, *et al.* Isolation of *Mycoplasma pneumoniae* from the synovial fluid of a hypogammaglobulinaemic patient in a survey of patients with inflammatory polyarthritis. *Ann Rheum Dis* 1978; 37: 180–182.

23 Furr PM, Taylor-Robinson D, Webster AD. Mycoplasmas and ureaplasmas in patients with hypogammaglobulinaemia and their role in arthritis: microbiological observations over twenty years. *Ann Rheum Dis* 1994; 53: 183–187.

24 Dumke R, Jacobs E. Antibody response to *Mycoplasma pneumoniae*: protection of host and influence on outbreaks? *Front Microbiol* 2016; 7: 39.

25 Meyer Sauteur PM, de Groot RCA, Estevao SC, *et al.* The role of B cells in carriage and clearance of *Mycoplasma pneumoniae* from the respiratory tract of mice. *J Infect Dis* 2018; 217: 298–309.

26 Meyer Sauteur PM, Seiler M, Truck J, *et al.* Diagnosis of *Mycoplasma pneumoniae* pneumonia with measurement of specific antibody-secreting cells. *Am J Respir Crit Care Med* 2019; 200: 1066–1069.

27 van Belkum A, Verkaik NJ, de Vogel CP, *et al.* Reclassification of *Staphylococcus aureus* nasal carriage types. *J Infect Dis* 2009; 199: 1820–1826.

28 Verkaik NJ, Lebon A, de Vogel CP, *et al.* Induction of antibodies by *Staphylococcus aureus* nasal colonisation in young children. *Clin Microbiol Infect* 2010; 16: 1312–1317.

29 Murphy KP. Janeway's Immunobiology. New York, Garland, 2012.

30 Duffy MF, Walker ID, Browning GF. The immunoreactive 116 kDa surface protein of *Mycoplasma pneumoniae* is encoded in an operon. *Microbiology* 1997; 143: 3391–3402.

31 Leith DK, Trevino LB, Tully JG, *et al.* Host discrimination of *Mycoplasma pneumoniae* proteinaceous immunogens. *J Exp Med* 1983; 157: 502–514.

32 Brunner H, Greenberg HB, James WD, *et al.* Antibody to *Mycoplasma pneumoniae* in nasal secretions and sputa of experimentally infected human volunteers. *Infect Immun* 1973; 8: 612–620.

33 Pollard AJ, Bijker EM. A guide to vaccinology: from basic principles to new developments. *Nat Rev Immunol* 2020; 21: 83–100.

34 Weight CM, Venturini C, Pojar S, *et al.* Microinvasion by *Streptococcus pneumoniae* induces epithelial innate immunity during colonisation at the human mucosal surface. *Nat Commun* 2019; 10: 3060.

35 Horton RE, Vidarsson G. Antibodies and their receptors: different potential roles in mucosal defense. *Front Immunol* 2013; 4: 200.